Overview

Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R for Cancer Treatment

Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The study will be non randomized, open label, dose rising study in cancer patients. Cancer treatment is consisting of 2 different drugs: Oshadi D and Oshadi R that will be administered orally. The study will include two sessions: - A single dose period to evaluate acute toxicity of each drug - Consecutive multiple increment dose escalation period of both drugs to determine the long-term safety, and the anticancer activity.
Phase:
Phase 1
Details
Lead Sponsor:
Oshadi Drug Administration